NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Price Target & More

$8.38 +0.05 (+0.60 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$8.38

Today's Range$8.29 - $8.49

52-Week Range$7.80 - $18.00

Volume351,360 shs

Average Volume453,875 shs

Market Capitalization$879.58 million

P/E Ratio-6.60

Dividend YieldN/A

Beta0.4

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:LXRX

CUSIP52887210

Webwww.lexpharma.com

Phone281-863-3000

Debt

Debt-to-Equity Ratio4.44%

Current Ratio2.59%

Quick Ratio2.58%

Price-To-Earnings

Trailing P/E Ratio-6.60

Forward P/E Ratio-5.86

P/E GrowthN/A

Sales & Book Value

Annual Sales$90.33 million

Price / Sales9.80

Cash FlowN/A

Price / CashN/A

Book Value$0.49 per share

Price / Book17.10

Profitability

EPS (Most Recent Fiscal Year)($1.27)

Net Income$-129,050,000.00

Net Margins-142.86%

Return on Equity-143.31%

Return on Assets-34.88%

Miscellaneous

Employees174

Outstanding Shares105,590,000

How to Become a New Pot Stock Millionaire

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals (NASDAQ:LXRX) posted its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.12. The biopharmaceutical company earned $33.05 million during the quarter, compared to analysts' expectations of $29.84 million. Lexicon Pharmaceuticals had a negative return on equity of 143.31% and a negative net margin of 142.86%. Lexicon Pharmaceuticals's revenue for the quarter was up 43.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.31) earnings per share. View Lexicon Pharmaceuticals' Earnings History.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Lexicon Pharmaceuticals.

What price target have analysts set for LXRX?

5 brokerages have issued 1 year price targets for Lexicon Pharmaceuticals' shares. Their predictions range from $10.00 to $40.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $24.50 in the next year. View Analyst Ratings for Lexicon Pharmaceuticals.

What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (3/21/2018)
2. Wedbush analysts commented, "Management announced the initiation of its second global Phase 2/3 clinical trial for Plinabulin (for the prevention of chemotherapy-induced neutropenia CIN). Study 106, initiated in China, is enrolling patients who receive TAC (taxotere, doxorubicin and cyclophosphamide) chemotherapy, which often results in severe neutropenia, to demonstrate Plinabulin’s superiority compared with Neulasta, a G-CSF." (11/30/2017)
3. Cowen Inc analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)

Who are some of Lexicon Pharmaceuticals' key competitors?

Some companies that are related to Lexicon Pharmaceuticals include Phibro Animal Health (PAHC), MyoKardia (MYOK), Madrigal Pharmaceuticals (MDGL), Enanta Pharmaceuticals (ENTA), Innoviva (INVA), Prestige Brands (PBH), Xencor (XNCR), Akcea Therapeutics (AKCA), Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Immuron (IMRN), ImmunoGen (IMGN), Prothena (PRTA), TherapeuticsMD (TXMD), Myovant Sciences (MYOV) and Endo International (ENDP).

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the folowing people:

Mr. Lonnel Coats, Pres, CEO & Director (Age 53)
Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 53)
Dr. Alan J. Main, Exec. VP of Commercial Supply Operations (Age 64)
Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 55)
Dr. Praveen Tyle, Exec. VP of R&D (Age 58)

Has Lexicon Pharmaceuticals been receiving favorable news coverage?

Press coverage about LXRX stock has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 48.08 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $8.38.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $879.58 million and generates $90.33 million in revenue each year. The biopharmaceutical company earns $-129,050,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.

MarketBeat Community Rating for Lexicon Pharmaceuticals (LXRX)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		265 (Vote Outperform)
Underperform Votes:		212 (Vote Underperform)
Total Votes:		477

MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Lexicon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $24.50, suggesting that the stock has a possible upside of 192.36%. The high price target for LXRX is $40.00 and the low price target for LXRX is $10.00. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Buy
Consensus Rating Score:	2.20	2.20	2.80	2.80
Ratings Breakdown:	1 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$24.50	$24.00	$28.50	$28.75
Price Target Upside:	192.36% upside	171.19% upside	182.46% upside	138.99% upside

Lexicon Pharmaceuticals (NASDAQ:LXRX) Consensus Price Target History

Price Target History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/16/2018	Wedbush	Boost Price Target	Outperform -> Outperform	$38.00 -> $40.00	Medium
2/23/2018	Needham & Company LLC	Downgrade	Buy -> Hold		High
2/14/2018	JPMorgan Chase	Downgrade	Neutral -> Underweight	$15.00 -> $10.00	High
8/1/2017	Cowen	Reiterated Rating	Hold		High
5/3/2017	HC Wainwright	Set Price Target	Buy	$27.00	High
3/7/2017	Citigroup	Boost Price Target	Buy	$24.00 -> $28.00	N/A
8/5/2016	Stifel Nicolaus	Boost Price Target	Buy	$25.00 -> $26.00	N/A

(Data available from 4/21/2016 forward)

Lexicon Pharmaceuticals (NASDAQ:LXRX) Earnings History and Estimates Chart

Earnings by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.42)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.41)	($0.41)	($0.41)
Q2 2018	1	($0.38)	($0.38)	($0.38)
Q3 2018	1	($0.32)	($0.32)	($0.32)
Q4 2018	1	($0.31)	($0.31)	($0.31)

Lexicon Pharmaceuticals (NASDAQ LXRX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		($0.43)					N/A
2/22/2018	Q4 2017	($0.43)	($0.31)	$29.84 million	$33.05 million	View	N/A
11/8/2017	Q3 2017	($0.36)	($0.2910)	$27.97 million	$26.94 million	View	N/A
8/1/2017	Q2 2017	($0.45)	($0.33)	$18.34 million	$12.00 million	View	Listen
5/2/2017	Q1 2017	($0.44)	($0.33)	$14.81 million	$18.29 million	View	N/A
3/3/2017	Q4 2016	($0.51)	($0.31)	$15.56 million	$23.00 million	View	N/A
11/1/2016	Q316	($0.50)	($0.35)	$9.68 million	$27.70 million	View	N/A
8/4/2016	Q216	($0.40)	($0.37)	$12.36 million	$20.10 million	View	N/A
5/3/2016	Q1	($0.30)	($0.34)	$11.11 million	$12.50 million	View	N/A
3/1/2016	Q415	($0.38)	$0.76	$21.50 million	$127.30 million	View	N/A
11/6/2015	Q3	($0.36)	($0.34)	$0.44 million	$0.57 million	View	N/A
8/7/2015	Q215	($0.32)	($0.27)	$0.45 million	$376.00 million	View	N/A
4/29/2015	Q115	($0.04)	($0.04)	$1.10 million	$1.78 million	View	N/A
11/4/2014	Q3	($0.05)	($0.05)	$0.16 million	$0.40 million	View	N/A
8/7/2014	Q214	($0.05)	($0.05)	$0.13 million	$0.68 million	View	N/A
5/8/2014	Q114	($0.05)	($0.06)	$0.12 million	$277.00 million	View	N/A
2/28/2014	Q413	($0.06)	($0.03)	$1.66 million	$1.40 million	View	N/A
11/12/2013	Q3	($0.01)	($0.06)	$1.59 million	$0.2380 million	View	Listen
7/30/2013	Q2 2013	($0.35)	($0.42)	$0.28 million	$0.21 million	View	N/A
5/10/2013	Q1 2013	($0.35)	($0.35)	$0.32 million	$0.36 million	View	N/A
2/21/2013	Q4 2012	($0.05)	($0.05)	$0.37 million	$0.2180 million	View	N/A
11/6/2012	Q312	($0.06)	($0.06)			View	N/A
7/31/2012	Q2 2012	($0.42)	($0.38)			View	N/A
5/3/2012	Q1 2012	($0.49)	($0.39)			View	N/A
2/22/2012	Q4 2011	($0.56)	($0.64)			View	N/A
11/1/2011	Q3 2011	($0.63)	($0.54)			View	N/A
8/8/2011	Q2 2011	($0.63)	($0.52)			View	N/A
5/3/2011	Q1 2011	($0.49)	($0.59)			View	N/A
2/24/2011	Q4 2010	($0.56)	($0.48)			View	N/A
11/5/2010	Q3 2010	($0.56)	($0.57)			View	N/A
8/9/2010	Q2 2010	($0.49)	($0.52)			View	N/A
5/10/2010	Q1 2010	($0.49)	($0.92)			View	N/A
2/23/2010	Q4 2009	($0.98)	($0.91)			View	N/A
10/27/2009	Q3 2009	($0.98)	($0.97)			View	N/A
7/28/2009	Q2 2009	($1.12)	($1.02)			View	N/A
4/28/2009	Q1 2009	($0.91)	($1.13)			View	N/A
2/25/2009	Q4 2008	($1.19)	($0.79)			View	N/A
10/30/2008	Q3 2008	($1.12)	($1.03)			View	N/A
7/29/2008	Q2 2008	($1.12)	($1.02)			View	N/A
4/29/2008	Q1 2008	($0.84)	($0.92)			View	N/A
3/6/2008	Q4 2007	($0.91)	($0.62)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Lexicon Pharmaceuticals (NASDAQ:LXRX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%

Insider Trading History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/17/2017	Public Equities L.P. Invus	Director	Buy	180,727	$10.11	$1,827,149.97
11/15/2017	Lonnel Coats	CEO	Buy	10,000	$9.91	$99,100.00	42,985
11/14/2017	Jeffrey L Wade	EVP	Buy	2,000	$9.48	$18,960.00	50,597
11/14/2017	Public Equities L.P. Invus	Director	Buy	575,946	$9.64	$5,552,119.44
11/10/2017	Public Equities L.P. Invus	Director	Buy	145,680	$9.74	$1,418,923.20
9/15/2017	Lonnel Coats	Insider	Buy	30,000	$12.54	$376,200.00
9/15/2017	Sam L Barker	Director	Buy	1,000	$12.50	$12,500.00	25,623
6/6/2016	James F Tessmer	VP	Sell	1,500	$15.00	$22,500.00	17,446
5/23/2016	James F Tessmer	VP	Sell	6,000	$13.00	$78,000.00	21,946
12/12/2014	C.V. Invus	Director	Buy	150,000	$0.88	$132,000.00
12/10/2014	C.V. Invus	Director	Buy	315,896	$0.90	$284,306.40
11/26/2014	International S.C.A. Artal	Director	Buy	149,253,731	$1.01	$150,746,268.31
10/25/2013	Bryan A Kleinlein	CFO	Sell	227,626	$0.13	$29,591.38
10/9/2013	Bryan A Kleinlein	CFO	Sell	83,281	$0.19	$15,823.39
7/9/2013	Bryan A Kleinlein	CFO	Sell	88,235	$0.11	$9,705.85
6/27/2013	Alexander Richard Walsh	CEO	Sell	160,000	$0.13	$20,800.00
6/18/2013	Alexander Richard Walsh	CEO	Sell	220,000	$0.18	$39,600.00
6/7/2013	Alexander Richard Walsh	CEO	Sell	170,000	$0.19	$32,300.00
11/21/2012	Alexander Richard Walsh	CEO	Sell	23,700	$0.34	$8,058.00
10/23/2012	International S.C.A. Artal	Director	Buy	3,000,000	$2.25	$6,750,000.00
10/3/2012	Alexander Richard Walsh	CEO	Sell	25,000	$0.30	$7,500.00

(Data available from 1/1/2013 forward)

Lexicon Pharmaceuticals (NASDAQ LXRX) News Headlines

Source:

Date	Headline
	3 Top Biotech Stocks to Buy Right Now finance.yahoo.com - April 21 at 8:16 AM
	Analysts Expect Lexicon Pharmaceuticals (LXRX) to Post -$0.45 Earnings Per Share www.americanbankingnews.com - April 20 at 5:24 AM
	Lexicon Pharmaceuticals (LXRX) Downgraded to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 19 at 8:31 PM
	Q1 2018 EPS Estimates for Lexicon Pharmaceuticals (LXRX) Lowered by Wedbush www.americanbankingnews.com - April 18 at 7:52 AM
	Lexicon Pharmaceuticals (LXRX) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 18 at 3:21 AM
	Lexicon Pharmaceuticals (LXRX) Upgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 17 at 9:49 PM
	Wedbush Boosts Lexicon Pharmaceuticals (LXRX) Price Target to $40.00 www.americanbankingnews.com - April 16 at 8:45 AM
	BidaskClub Lowers Lexicon Pharmaceuticals (LXRX) to Sell www.americanbankingnews.com - April 14 at 10:43 AM
	Lexicon Pharmaceuticals (LXRX) Lowered to Sell at BidaskClub www.americanbankingnews.com - April 14 at 12:17 AM
	Lexicon Pharmaceuticals (LXRX) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - April 10 at 9:26 PM
	Lexicon Pharmaceuticals (LXRX) Lowered to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 7 at 10:32 AM
	$22.14 Million in Sales Expected for Lexicon Pharmaceuticals (LXRX) This Quarter www.americanbankingnews.com - April 5 at 4:34 AM
	Analysts Anticipate Lexicon Pharmaceuticals (LXRX) Will Announce Earnings of -$0.43 Per Share www.americanbankingnews.com - April 3 at 9:18 AM
	Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018 feeds.benzinga.com - April 3 at 7:51 AM
	Lexicon Pharma (LXRX) Announces EMA Acceptance of MAA for Sotagliflozin to Treat Adults With Type 1 Diabetes www.streetinsider.com - March 30 at 8:16 AM
	Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes finance.yahoo.com - March 29 at 8:20 AM
	Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes feeds.benzinga.com - March 29 at 3:13 AM
	Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes finance.yahoo.com - March 28 at 8:23 AM
	Lexicon Pharma (LXRX) Submits NDA to FDA for Sotagliflozin to Treat Adults With Type 1 Diabetes www.streetinsider.com - March 26 at 5:23 PM
	Lexicon Pharmaceuticals (LXRX) Raised to Hold at BidaskClub www.americanbankingnews.com - March 26 at 1:58 PM
	Lexicon Pharmaceuticals (LXRX) Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 26 at 12:44 PM
	Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes finance.yahoo.com - March 26 at 8:17 AM
	Lexicon Pharmaceuticals, Inc. (LXRX) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - March 24 at 3:36 AM
	Lexicon Pharmaceuticals (LXRX) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - March 23 at 11:52 PM
	Edited Transcript of LXRX earnings conference call or presentation 22-Feb-18 1:00pm GMT finance.yahoo.com - March 22 at 5:40 PM
	Brokerages Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Quarterly Sales of $22.14 Million www.americanbankingnews.com - March 19 at 8:18 AM
	Research Analysts Set Expectations for Lexicon Pharmaceuticals, Inc.'s Q1 2018 Earnings (LXRX) www.americanbankingnews.com - March 15 at 6:44 AM
	Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $28.32 Million www.americanbankingnews.com - March 2 at 1:32 PM
	Lexicon Pharmaceuticals Inc (LXRX) Files 10-K for the Fiscal Year Ended on December 31, 2017 finance.yahoo.com - March 1 at 5:55 PM
	Lexicon Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire (press release) globenewswire.com - February 28 at 8:13 AM
	Brokerages Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) to Post -$0.38 EPS www.americanbankingnews.com - February 28 at 3:14 AM
	Contrasting Conatus Pharmaceuticals (CNAT) & Lexicon Pharmaceuticals (LXRX) www.americanbankingnews.com - February 27 at 5:20 PM
	Lexicon Pharmaceuticals, Inc. (LXRX) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - February 27 at 3:40 AM
	Lexicon Pharmaceuticals (LXRX) Upgraded by BidaskClub to Hold www.americanbankingnews.com - February 24 at 10:54 PM
	Lexicon Pharmaceuticals (LXRX) Announces Earnings Results www.americanbankingnews.com - February 23 at 12:55 PM
	Lexicon Pharmaceuticals (LXRX) Lowered to "Hold" at Needham & Company LLC www.americanbankingnews.com - February 23 at 12:42 PM
	Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update - GlobeNewswire (press release) globenewswire.com - February 22 at 8:15 AM
	Lexicon Pharmaceuticals, Inc. to Host Earnings Call finance.yahoo.com - February 22 at 8:15 AM
	Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update finance.yahoo.com - February 22 at 8:15 AM
	Lexicon Pharmaceuticals (LXRX) Scheduled to Post Quarterly Earnings on Thursday www.americanbankingnews.com - February 22 at 1:30 AM
	Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast ... - GlobeNewswire (press release) globenewswire.com - February 17 at 8:11 AM
	Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast on February 22, 2018 finance.yahoo.com - February 16 at 8:14 AM
	Here's Why Lexicon Pharmaceuticals Dropped as Much as 13.6% Today finance.yahoo.com - February 14 at 3:43 PM
	Here's Why Lexicon Pharmaceuticals Dropped as Much as 13.6% Today www.fool.com - February 14 at 3:20 PM
	Lexicon Pharmaceuticals (LXRX) Cut to Underweight at JPMorgan Chase & Co. www.americanbankingnews.com - February 14 at 10:38 AM
	$29.80 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter www.americanbankingnews.com - February 13 at 4:32 AM
	Lexicon Pharmaceuticals (LXRX) Downgraded by BidaskClub www.americanbankingnews.com - February 5 at 11:58 PM
	Lexicon Pharmaceuticals (LXRX) Downgraded by ValuEngine www.americanbankingnews.com - February 4 at 11:22 PM
	Lexicon Pharmaceuticals, Inc. (LXRX) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - February 2 at 3:15 AM
	-$0.43 EPS Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter www.americanbankingnews.com - January 25 at 11:34 AM

Lexicon Pharmaceuticals (NASDAQ:LXRX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Income Statement, Balance Sheet and Cash Flow Statement

Lexicon Pharmaceuticals (NASDAQ LXRX) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff